quarter meaning expect
sustain evid low-risk tavr inflect guidanc
base case reflect optim toward v-shape
recoveri remain ow pt
quarter better base case total
revenu estim versu peer averag two way
look quarter comp stabl perform would yield
tavr revenu would edward
deliv first month quarter tavr
pace growth follow drop last
week impli growth quarter growth would impli
result normal also compar favor
peer compani shi away market share dynam share gain
like persist physician dilig point better
profil sapien coronari access pace evolut low risk patient
ep vs mse gross margin vs mse oper
pace recoveri follow expect exhibit trough procedur
growth manag guid gradual recoveri follow
resembl origin expect guidanc reflect exist
trend low end recoveri mid high end dilig suggest
emerg procedur show modest improv trough level
improv earli next week given recent action
state well overal case progress improv return
normalci repres upsid recoveri model project
recaptur may fulli risk adjust manag recoveri
model assum v-shape recoveri reflect neg impact
materi disrupt referr channel potenti
refin model move slightli mid-point rais covid-
adjust corpor organ growth flat tavr organ growth
adjust revenu assumpt across segment tavr surgic
structur heart critic reflect
estim tmtt repres given strain icu capac well
medic technolog unit state america
unless otherwis note metric base modelwar
consensu data provid thomson reuter estim
seek busi
compani cover morgan stanley research
result investor awar firm may
conflict interest could affect object
morgan stanley research investor consid
morgan stanley research singl factor make
invest decis
analyst certif import disclosur
refer disclosur section locat end
fact busi remain nascent stage develop ep
reflect level respect
exhibit detail model chang exhibit key guidanc
revisit two-year data discuss extens
two-year data note see tavr maintain edg savr
year despit narrow curv rel year notwithstand
lack clear link valv thrombosi vt clinic outcom rise
vt year worth monitor base leaflet format seen
evolut sapien valv
upcom catalyst bucket litig clinic litig
catalyst center around legal battl pascal abbott
mitraclip includ rule first germani hear occur
last month us trial schedul may subsequ rule
second germani rule subsequ rule remind high court
england wale last month deliv win abbott uk trial
although note uk repres immateri tmtt sale believ
outcom germani pronounc impact given germani
repres major pascal revenu impact perman
injunct could chip away bp corpor growth clinic side
expect see earli data evoqu pascal
cardioband studi upcom euro pcr confer may posit
develop mitral import head could
group coverag three phase phase includ supplier
phase includ discretionari implant capit intens busi
see edward rel emerg phase recoveri stori
addit phase recoveri model low-risk expans pascal roll-out
continu underpin thesi top low-risk inflect drive tavr
momentum see tavr savr gain equal foot funnel
widen patient across risk spectrum come view creat
longer tail tavr expans increas edward market access reinforc
growth progress reiter ow revis pt
author materi act capac attorney
hold materi intend either legal opinion
legal advic inform provid herein provid possibl
outcom probabl outcom result legal disput
controversi depend varieti factor includ limit
parti histor relationship law pertain case rel litig talent
trial locat juri composit judg composit investor contact
legal advisor issu law relat subject matter
tavr market expans continu low risk mitral catalyst ahead
dcf-base analysi reect tavr market reach global
see gradual expans low risk popul follow low-risk data
complement growth rate higher risk us eu popul ew share declin
time remain market leader
long-term potenti market expans
lower risk remain underappreci
drive out-performance time
see market expans billion
penetr durabl reect
continu see tavr drive
long-term ebit margin high
mitral visibl remain low faster
develop could support bull case
project robust mitral opportun
potenti market size aortic
market discount heavili base
case reect uncertainti futur
market
view descript risk reward theme
risk prove bridg far valv
durabl remain outstand issu
younger patient still tavr market
grow billion limit low
risk intermedi risk traction sapien
share slip traction
acceler competit boston
off-set continu product
materi slower peer
thomson reuter morgan stanley research morgan stanley institut equiti divis probabl
bull base bear case scenario play estim impli volatil data option market
apr gure approxim risk-neutr probabl stock reach beyond scenario price
either three-month one-year time view explan option probabl methodolog
share tavr market grow
bn tavr increasingli becom
therapi choic even low risk
patient drive penetr
expect price declin
lower expect rate
base case ep support
time tavr market reach
global see gradual
expans low risk popul
follow low-risk data
complement growth rate higher risk
us eu popul ew share declin
time remain market
leader coapt result mitral path
forward key edward trial timelin
launch need addit clariti oper
leverag acceler long-term margin
penetr tavr lower risk popul
critic near term medium term
increas visibl structur heart
portfolio key durabl long term growth
china india
view explan region hierarchi
research highest favor quintil
expect
expect
robust commerci traction boston
abbott/st jude long term
potenti pipelin develop failur
us european reimburs pressur
price time
fund exposur held mspb inform may
inconsist may reect broader market
exposur sector total net exposur
across sector long exposur short exposur
million except ep
exhibit financi
sale
sale
sale
sale
high end
high end
equival
prepaid expens ca
net chang work capit
oper
invest intang asset
invest unconsolid affili
proce asset disposit
proce sale busi
proce note receiv
invest
proce issuanc long-term debt
payment long-term debt
proce issuanc short-term debt
payment short-term debt
chang equiti net tax benefit
payment relat ar securit net
financ
effect currenc exchang
